LASN01 is a novel, clinical stage antibody that blocks inflammatory cytokine and chemokine release in in vitro studies using orbital fibroblasts from thyroid eye disease (TED) patients

LASN01 - Lassen Therap

Tepezza (teprotumumab-trbw) - Roche, Amgen

James Swaney 1; Shira Geller 1; Yasmin Vasquez 1; Andrea Kossler 2; Rona Silkiss 3; Deborah Witherden 1; DavidKing 1

Oct 4, 2024